Article Versions Notes

Huang Y-E, Tsai Y-H, Huang Y-J, Lung J-H, Ho K-W, Yen T-C, Chan S-C, Chen S-T, Tsai M-F, Hung M-S. ¹⁸F-Fluorodeoxyglucose PET/CT for Early Prediction of Outcomes in Patients with Advanced Lung Adenocarcinomas and EGFR Mutations Treated with First-Line EGFR-TKIs. Cancers. 2022; 14(6):1507. https://doi.org/10.3390/cancers14061507

Huang, Yu-Erh, Ying-Huang Tsai, Yu-Jie Huang, Jr-Hau Lung, Kuo-Wei Ho, Tzu-Chen Yen, Sheng-Chieh Chan, Shu-Tian Chen, Ming-Feng Tsai, and Ming-Szu Hung. 2022. "¹⁸F-Fluorodeoxyglucose PET/CT for Early Prediction of Outcomes in Patients with Advanced Lung Adenocarcinomas and EGFR Mutations Treated with First-Line EGFR-TKIs" Cancers 14, no. 6: 1507. https://doi.org/10.3390/cancers14061507

Huang, Y.-E., Tsai, Y.-H., Huang, Y.-J., Lung, J.-H., Ho, K.-W., Yen, T.-C., Chan, S.-C., Chen, S.-T., Tsai, M.-F., & Hung, M.-S. (2022). ¹⁸F-Fluorodeoxyglucose PET/CT for Early Prediction of Outcomes in Patients with Advanced Lung Adenocarcinomas and EGFR Mutations Treated with First-Line EGFR-TKIs. Cancers, 14(6), 1507. https://doi.org/10.3390/cancers14061507